Definitive Contract 75A50125C00017
Award Date
9/30/25
Potential Completion Date
7/3/30
Potential Value
$339M
Awardee
Cidara Therapeutics Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $65,867,803.99 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to VIR Biotechnology, Inc., a self-certified small disadvantaged business. The contract is for the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. This contract was awarded under a Broad...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This federal contract award, with a ceiling value of $360,378,153.90, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Regeneron Pharmaceuticals Inc. for the development of "Novel Antibodies Against Influenza Virus, Emerging, Re-Emerging, and Pre-Emerging Pathogens." The contract is a Definitive Contract with a Cost Sharing pricing type and has an ultimate completion date of September 24, 2027. The award is not associated with a set-aside...
This is a $330,136,249.00 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to 4J Therapeutics Inc. to demonstrate the versatility and efficacy of their programmable antiviral technology platform. The purpose is to assemble a preclinical package for LNA14 and perform a Phase 1a study in healthy adults. The contract is not set aside and is the result of a Broad Agency Announcement (BAA) solicitation issued by the Biomedical Advanced...
This is a $204,984,698.95 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Biocryst Pharmaceuticals Inc. for the advance development of a new antiviral agent for influenza under the Pandemic Influenza Preparedness program. The contract does not have a set-aside designation, indicating Biocryst competed for the award in the open market. Biocryst is a biotechnology...
This is a $16,382,387.80 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to PPD Development, LP. The contract is for clinical services described in Tasks 1 through 15 under the ASPR-16-05933 requirement, which is part of the Medical Countermeasures Clinical Studies Network IDIQ contract vehicle. The contract is for a Heterologous Prime Boost Influenza Vaccine Trial and does not have a set-aside...
This is a $749,999.01 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Red Queen Therapeutics Inc., a self-certified small disadvantaged business. The contract is for research and development of a rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections. This contract is not set aside and has an ultimate completion date of...
This federal contract award, valued at $23,257,222.47, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The purpose of the contract is to provide medical countermeasures (MCMs), such as vaccines and adjuvants, for pandemic preparedness and response. The contract was awarded to Seqirus Inc., a division of the global biotechnology company CSL Seqirus, which is a leading provider of MCMs to the...
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to The Medicines Company. The contract, which does not have a set-aside designation, is valued at $98,144,230.00 and runs through September 30, 2030. The purpose of the contract is to advance the development of The Medicines Company's portfolio of anti-infective programs. The contract updates the address, principal investigator, and...
This is a $113,182,532.15 definitive contract awarded to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions, by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for pandemic preparedness and response. The contract is to establish a platform for diagnosis and surveillance of emerging threats and is not designated with a set-aside. The original solicitation was a Broad Agency Announcement from the Biomedical Advanced Research and Development...